Skip to content

Anti-sebum activity of Nia-Zelaic Oil Control Face Serum

A Clinical Study to Evaluate Anti-sebum activity of Nia-Zelaic Oil Control Face Serum - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/06/089160
Enrollment
10
Registered
2025-06-19
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product: Nia-Zelaic Oil Control Face Serum: Dose: Gently use approx. 0.5ml Nia-Zelaic Oil Control Face Serum on half face [approx. 2mg/cm2] Route of Administration: Topical Subj

Sponsors

Honasa Consumer Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Gender: Male or Female with age 18-45 2) Subjects with oily skin. 3) Subjects willing to give written informed consent 4) Women of child bearing potential must have a negative urine pregnancy test prior to study entry. 5) Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events. 6) Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study.

Exclusion criteria

Exclusion criteria: 1. Subjects who are pregnant, breast-feeding, or planning to become pregnant during the study. 2. Have any evidence of systemic cancer, squamous cell carcinoma, basal cell carcinoma, in the last 5 years, or any other confounding skin condition. 3. Have open sores or open lesions in the treatment area(s). 4. Have any condition that, in the opinion of the investigator, would confound the safety and/or efficacy assessments of the product. 5. Have participated in any interventional clinical trial in the previous 90 days. 6. Have a known sensitivity to any of the constituents of the test product including sensitivities to product ingredients 7. Have used, are using, or are planning to use immunosuppressive or immunomodulatory medication (i.e., biologics), including corticosteroids. Have not skin related issues

Design outcomes

Primary

MeasureTime frame
1. Change in SebumTimepoint: At Day1 T0, T3hrs, T6hrs

Secondary

MeasureTime frame
Not ApplicableTimepoint: Not Applicable

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org8937015757

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026